{"transactions":[{"id":1520873,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":91223,"kind":"person","name":"Mika Yuval","position":1,"cik":"0001949285","reported_name":"Mika Yuval","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock, par value $0.0001 per share (\"Common Stock\")","published_at":"2024-05-10T21:25:20.000Z","date":"2024-05-08","kind":"grant","planned":false,"acquired":true,"shares":69333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest as follows: (i) 10,400 RSUs will vest on May 18, 2025, and (ii) the remaining 58,933 RSUs will vest in equal installments on August 18, 2025, November 18, 2025, December 18, 2025, May 18, 2026, August 18, 2026, November 18, 2026, March 25, 2027, May 18, 2027, August 18, 2027, November 18, 2027, March 25, 2028 and May 18, 2028, subject to the Reporting Person's continuous service through such dates."}],"balance_after":158905,"source":{"system":"sec-edgar","filing":"0001104659-24-060006","document":"tm2414108-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000110465924060006/tm2414108-7_4seq1.xml","form_type":"4"}},{"id":1824227,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":91223,"kind":"person","name":"Mika Yuval","position":1,"cik":"0001949285","reported_name":"Mika Yuval","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock, par value $0.0001 per share (\"Common Stock\")","published_at":"2023-07-24T21:10:39.000Z","date":"2023-07-20","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest over a three-year period as follows: (i) 34% of the shares will vest on the 18-month anniversary of the grant date, (ii) 33% the shares will vest on the two-year anniversary of the grant date, and (iii) 33% the shares will vest on the three-year anniversary of the grant date, subject to the Reporting Person's continuous service through such dates."}],"balance_after":89572,"source":{"system":"sec-edgar","filing":"0001104659-23-083498","document":"tm2321855-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000110465923083498/tm2321855-5_4seq1.xml","form_type":"4"}},{"id":1884808,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":91223,"kind":"person","name":"Mika Yuval","position":1,"cik":"0001949285","reported_name":"Mika Yuval","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Nonstatutory Stock Option (Right to Buy)","published_at":"2023-05-19T21:58:08.000Z","date":"2023-01-26","kind":"grant","planned":false,"acquired":true,"shares":234242,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On January 30, 2023, the Reporting Person filed a Form 4 which inadvertently (i) misstated the expiration date of one class of nonstatutory stock options (\"NSOs\") and (ii) misstated the vesting schedule for such NSOs. In accordance with Instruction 9(b) to Form 4, this amendment is filed solely to (i) correct the incorrect expiration date in Table II, Column 6 to August 17, 2032 , and (ii) correct the incorrect vesting schedule set forth in the footnote corresponding to such NSOs, which is reproduced in this amendment with the correct vesting schedule; as provided in that instruction, the remainder of the information in the original filing is not restated in this amendment, and no other amendment is made to the original filing."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Received in the Business Combination in exchange for a nonstatutory stock option to acquire 503,746 shares of Legacy Orchestra Common Stock for $4.65 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The NSOs vest over a three-year period as follows: (i) 33% of the underlying shares vested on the grant date and (ii) 67% of the underlying shares have vested and will vest in equal installments on a quarterly basis on the last day of each quarter, starting with September 30, 2022, subject to the Reporting Person's continuous service through such dates. The grant date is August 18, 2022."}],"balance_after":234242,"derivative":{"exercise_price":10,"expiration_date":"2032-08-17","underlying":"Common Stock","underlying_shares":234242},"source":{"system":"sec-edgar","filing":"0001213900-23-041632","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000121390023041632/ownership.xml","form_type":"4/A","original_submission_date":"2023-01-30"}},{"id":1902983,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":91223,"kind":"person","name":"Mika Yuval","position":1,"cik":"0001949285","reported_name":"Mika Yuval","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Right to Receive Earnout Shares","published_at":"2023-05-06T00:20:00.000Z","date":"2023-04-12","kind":"exercise","planned":false,"acquired":false,"shares":8852,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the \"Initial Milestone Event\") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Initial Milestone Event occurred on April 12, 2023 and 8,852 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the \"Initial Milestone Event\") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The Initial Milestone Event occurred on April 12, 2023 and 8,852 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the \"Initial Milestone Event\") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Initial Milestone Event occurred on April 12, 2023 and 8,852 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the \"Initial Milestone Event\") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Initial Milestone Event occurred on April 12, 2023 and 8,852 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the \"Initial Milestone Event\") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Initial Milestone Event occurred on April 12, 2023 and 8,852 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement."}],"balance_after":8852,"derivative":{"underlying":"Common Stock","underlying_shares":8852},"source":{"system":"sec-edgar","filing":"0001213900-23-037029","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000121390023037029/ownership.xml","form_type":"4"}},{"id":1902982,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":91223,"kind":"person","name":"Mika Yuval","position":1,"cik":"0001949285","reported_name":"Mika Yuval","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock, par value $0.0001 per share (\"Common Stock\")","published_at":"2023-05-06T00:20:00.000Z","date":"2023-04-12","kind":"exercise","planned":false,"acquired":true,"shares":8852,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the \"Initial Milestone Event\") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The Initial Milestone Event occurred on April 12, 2023 and 8,852 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the \"Initial Milestone Event\") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Initial Milestone Event occurred on April 12, 2023 and 8,852 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement."}],"balance_after":49572,"source":{"system":"sec-edgar","filing":"0001213900-23-037029","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000121390023037029/ownership.xml","form_type":"4"}},{"id":1902972,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":91223,"kind":"person","name":"Mika Yuval","position":1,"cik":"0001949285","reported_name":"Mika Yuval","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Right to Receive Earnout Shares","published_at":"2023-05-06T00:13:07.000Z","date":"2023-01-26","kind":"grant","planned":false,"acquired":true,"shares":17704,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On January 30, 2023, the Reporting Person filed a Form 4 which inadvertently omitted the right to receive Earnout Shares (defined below). In accordance with Instruction 9(a) to Form 4, this amendment is filed to add the lines of information to Table II included here; as provided in that instruction, the remainder of the information in the original filing is not restated in this amendment. The original Form 4 also mistakenly indicated that the Reporting Person is a director of the Issuer; the Reporting Person is not a director of the Issuer."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."}],"balance_after":17704,"derivative":{"underlying":"Common Stock","underlying_shares":17704},"source":{"system":"sec-edgar","filing":"0001213900-23-037019","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000121390023037019/ownership.xml","form_type":"4/A","original_submission_date":"2023-01-30"}},{"id":2042321,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":91223,"kind":"person","name":"Mika Yuval","position":1,"cik":"0001949285","reported_name":"Mika Yuval","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Incentive Stock Option (Right to Buy)","published_at":"2023-01-31T02:36:58.000Z","date":"2023-01-26","kind":"grant","acquired":true,"shares":46500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Received in the Business Combination in exchange for an incentive stock option to acquire 100,000 shares of Legacy Orchestra Common Stock for $2.00 per share."}],"balance_after":46500,"derivative":{"exercise_price":4.3,"exercise_date":"2023-01-26","expiration_date":"2028-08-07","underlying":"Common Stock","underlying_shares":46500},"source":{"system":"sec-edgar","filing":"0001213900-23-006198","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000121390023006198/ownership.xml","form_type":"4"}},{"id":2042320,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":91223,"kind":"person","name":"Mika Yuval","position":1,"cik":"0001949285","reported_name":"Mika Yuval","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Nonstatutory Stock Option (Right to Buy)","published_at":"2023-01-31T02:36:58.000Z","date":"2023-01-26","kind":"grant","acquired":true,"shares":234242,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Received in the Business Combination in exchange for a nonstatutory stock option to acquire 503,746 shares of Legacy Orchestra Common Stock for $4.65 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The nonstatutory stock options vest over a three-year period as follows: (i) 33% of the underlying shares vested on the grant date and (ii) 67% of the underlying shares have vested and will vest in equal installments on a quarterly basis on the last day of each quarter, starting with the end of the first quarter after the grant date, subject to the Reporting Person's continuous service through such dates. The grant date is August 18, 2022."}],"balance_after":234242,"derivative":{"exercise_price":10,"expiration_date":"2032-08-25","underlying":"Common Stock","underlying_shares":234242},"source":{"system":"sec-edgar","filing":"0001213900-23-006198","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000121390023006198/ownership.xml","form_type":"4"}},{"id":2042319,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":91223,"kind":"person","name":"Mika Yuval","position":1,"cik":"0001949285","reported_name":"Mika Yuval","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Nonstatutory Stock Option (Right to Buy)","published_at":"2023-01-31T02:36:58.000Z","date":"2023-01-26","kind":"grant","acquired":true,"shares":69870,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Received in the Business Combination in exchange for a nonstatutory stock option to acquire 150,259 shares of Legacy Orchestra Common Stock for $2.00 per share."}],"balance_after":69870,"derivative":{"exercise_price":4.3,"exercise_date":"2023-01-26","expiration_date":"2028-08-07","underlying":"Common Stock","underlying_shares":69870},"source":{"system":"sec-edgar","filing":"0001213900-23-006198","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000121390023006198/ownership.xml","form_type":"4"}},{"id":2042318,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":91223,"kind":"person","name":"Mika Yuval","position":1,"cik":"0001949285","reported_name":"Mika Yuval","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock, par value $0.0001 per share (\"Common Stock\")","published_at":"2023-01-31T02:36:58.000Z","date":"2023-01-26","kind":"grant","acquired":true,"shares":40720,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities were issued on the closing date of the merger (the \"Business Combination\") contemplated by the Agreement and Plan of Merger, dated as of July 4, 2022, as amended by Amendment No. 1 thereto dated as of July 21, 2022 and Amendment No. 2 thereto dated as of November 21, 2022 (as amended, the \"Merger Agreement\"), by and among Orchestra BioMed Holdings, Inc. (f/k/a Health Sciences Acquisitions Corporation 2) (\"HSAC2\"), HSAC Olympus Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of HSAC2, and Orchestra BioMed, Inc., a Delaware corporation (\"Legacy Orchestra\"), in exchange for Legacy Orchestra securities."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Received in the Business Combination in exchange for 87,571 shares of common stock of Legacy Orchestra (\"Legacy Orchestra Common Stock\")."}],"balance_after":40720,"source":{"system":"sec-edgar","filing":"0001213900-23-006198","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000121390023006198/ownership.xml","form_type":"4"}}]}